Alligator Bioscience (BATS-CHIXE:ATORXS) - Aandelenkoers, Nieuws & Analyse

ATORXS Overzicht aandelen

A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. Meer informatie

ATORXS fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 51.67% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( SEK385M )

+ 1 meer risico

Alligator Bioscience AB (publ) Concurrenten

Arecor Therapeutics

AIM:AREC

UK£28.3m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Avacta Group

AIM:AVCT

UK£179.3m

ProBiotix Health

OFEX:PBX

UK£10.3m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Alligator Bioscience
Historische aandelenkoersen
Huidige aandelenkoers	SEK 0.80
52 Week Hoogtepunt	SEK 0.80
52 Week Laag	SEK 0.80
Bèta	1.15
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-91.53%
5 jaar verandering	-97.66%
Verandering sinds IPO	-97.75%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ATORXS	GB Biotechs	GB Markt
7D	0%	0.3%	2.2%
1Y	n/a	-18.3%	8.0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe ATORXS presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe ATORXS presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is ATORXS's price volatile compared to industry and market?
ATORXS volatility
ATORXS Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: ATORXS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ATORXS in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	58	Søren Bregenholt	www.alligatorbioscience.se

Alligator Bioscience AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Alligator Bioscience zich tot de beurswaarde?
ATORXS fundamentele statistieken
Marktkapitalisatie	SEK 384.75m
Inkomsten(TTM)	-SEK 212.87m
Inkomsten(TTM)	SEK 40.45m

9.5x

P/S-verhouding

-1.8x

Koers/Winstverhouding

Is ATORXS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ATORXS resultatenrekening (TTM)
Inkomsten	SEK 40.45m
Kosten van inkomsten	SEK 169.05m
Brutowinst	-SEK 128.59m
Overige uitgaven	SEK 84.28m
Inkomsten	-SEK 212.87m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

Jul 13, 2023

Winst per aandeel (EPS)	-0.34
Brutomarge	-317.87%
Nettowinstmarge	-526.20%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ATORXS op de lange termijn?

Bekijk historische prestaties en vergelijking

ATORXS Overzicht aandelen

Beloningen

Risicoanalyse

Alligator Bioscience AB (publ) Concurrenten

AIM:AREC

UK£28.3m

AIM:TRX

UK£40.6m

AIM:AVCT

UK£179.3m

OFEX:PBX

UK£10.3m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Recent updates

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Alligator Bioscience AB (publ), Annual General Meeting, May 07, 2025

Alligator Bioscience AB (Publ) Appoints Nomination Committee in Respect of AGM 2025

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Alligator Bioscience AB (Publ) Appoints Johan Giléus as Chief Financial Officer as of August 12, 2024

Alligator Bioscience Announces Completion of Enrollment in Mitazalimab Optimize-1 Study

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Plans to Adjust Size of Organization with Reduction of Approximately 20% to 25% of Current Workforce

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings released: kr0.88 loss per share (vs kr1.58 loss in FY 2021)

High number of new directors